CBIC notifies GST rate for COVID related medicines

Notification 12/2021-central tax rate
Print Friendly, PDF & Email

In exercise of the powers conferred by sub-section (1) of section 11 of the Central Goods and Services Tax Act, 2017 (12 of 2017) (hereafter in this notification referred to as “the said Act”), the Central Government, on being satisfied that it is necessary in the public interest so to do, on the recommendations of the Council, hereby exempts the goods specified in column (3) of the Table below, falling under the tariff item, sub-heading, heading or Chapter as specified in the First Schedule to the Customs Tariff Act, 1975 (51 of 1975), as the case may be, as specified in the corresponding entry in column (2) of the said Table, from so much of the central tax leviable thereon under section 9 of the said Act, as is in excess of the amount calculated at the rate as specified in corresponding entry in column

(4) of the aforesaid Table, namely:-


Sl. No. Chapter, Heading, Sub- heading or Tariff item Description of Goods Rate
(1) (2) (3) (4)
1 30 Tocilizumab Nil
2 30 Amphotericin B Nil
3 30 Remdesivir 2.5%
4 30 Heparin (anti-coagulant) 2.5%
5 30 Itolizumab 2.5%
6 30 Posaconazole 2.5%
7 30 Infliximab 2.5%
8 30 Bamlanivimab & Etesevimab 2.5%
9 30 Casirivimab & Imdevimab 2.5%
10 30 2-Deoxy-D-Glucose 2.5%
11 30 Favipiravir 2.5%
  1. This notification shall come into force from the 1st day of October, 2021 and remain in force up to and inclusive of the 31st December, 2021.

Related posts

CBIC clarifies the applicability of sub rule (1A) of Rule 89 for refund


CBIC notifies GST rates on services related to AFC Women’s Asia Cup 2022


Notification No. 03/2021 – Central Tax (Rate) – Time of payment of GST by the Real Estate Developers


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

error: Content is protected !!